Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Breast Neoplasm Female × palbociclib × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 149 Neoplasm Metastasis 22 Neoplasms 17 Sarcoma 10 Ovarian Neoplasms 10 Squamous Cell Carcinoma of Head and Neck 8 Pancreatic Neoplasms 8 Carcinoma, Non-Small-Cell Lung 7 Endometrial Neoplasms 6 Colorectal Neoplasms 6 Prostatic Neoplasms 5 Melanoma 5 Lymphoma, Non-Hodgkin 5 Head and Neck Neoplasms 5 Breast Diseases 5 Sarcoma, Ewing 4 Recurrence 4 Multiple Myeloma 4 Medulloblastoma 4 Lung Neoplasms 4 Carcinoma, Renal Cell 4 Triple Negative Breast Neoplasms 3 Rhabdomyosarcoma 3 Rhabdoid Tumor 3 Precursor Cell Lymphoblastic Leukemia-Lymphoma 3 Osteosarcoma 3 Neuroblastoma 3 Liposarcoma 3 Leukemia, Myeloid, Acute 3 Glioblastoma 3

Interventions

Fulvestrant 2 venetoclax 1 pyrotinib 1 pertuzumab 1 palbociclib 1 dalpiciclib 1 anlotinib 1 Tretinoin 1 Trastuzumab 1 Ropivacaine 1 Radiosurgery 1 Propofol 1 Patient Reported Outcome Measures 1 Paclitaxel 1 Ondansetron 1 Morphine 1 Letrozole 1 Induction Chemotherapy 1 Etoricoxib 1 Docetaxel 1 Diagnostic Imaging 1 Carboplatin 1 Capecitabine 1 Anastrozole 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03900884 2024-11-07

PALVEN

Peter MacCallum Cancer Centre, Australia

Phase 1 Active not recruiting

Breast Neoplasm Female

Data powered by HemOnc (CC BY 4.0) Colophon ⚡